Inflammatory bowel disease (IBD) is a chronic, recurrent, non-specific gastrointestinal disease with an unclear pathogenesis, and there is no curative treatment at present. As a multi-component natural traditional Chinese medicine, Coptidis Rhizoma shows the advantages of multi-target and multi-pathway regulation in the treatment of IBD with its rich chemical composition and unique pharmacological activity. Its core active ingredients are isoquinoline alkaloids, including berberine, coptisine, palmatine, berberrubine, etc., supplemented by flavonoids, lignans, organic acids, polysaccharides, terpenoids and other components, which have the effect of clearing heat and drying dampness,purgingfire and removing toxin. Modern pharmacological studies have confirmed that Coptidis Rhizoma and its active components exert therapeutic effects on IBD through multiple mechanisms, including antioxidative stress, anti-inflammatory, immunomodulatory, intestinal mucosal barrier protection, regulation of intestinal flora, glucose metabolism modulation, and cholinergic system regulation. This review summarizes the recent advances in the mechanisms and applications of Coptidis Rhizoma and its active ingredients in the treatment of IBD, providing a reference for the development of standardized clinical preparations of Coptidis Rhizoma.

Coptidis Rhizoma  /  inflammatory bowel disease  /  mucosal barrier  /  intestinal microflora  /  berberine  /  coptisine  /  palmatine  /  berberrubine